Sei Investments Co. Sells 13,346 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Sei Investments Co. trimmed its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 4.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 296,416 shares of the company's stock after selling 13,346 shares during the quarter. Sei Investments Co. owned about 0.50% of Twist Bioscience worth $13,774,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Barclays PLC boosted its holdings in Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company's stock worth $6,913,000 after acquiring an additional 104,420 shares in the last quarter. FMR LLC boosted its holdings in shares of Twist Bioscience by 6.0% in the 3rd quarter. FMR LLC now owns 218,561 shares of the company's stock worth $9,875,000 after buying an additional 12,327 shares during the last quarter. Avanza Fonder AB bought a new position in shares of Twist Bioscience during the 4th quarter valued at approximately $1,059,000. BNP Paribas Financial Markets grew its holdings in Twist Bioscience by 128.1% during the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company's stock valued at $1,718,000 after purchasing an additional 21,357 shares during the period. Finally, Principal Financial Group Inc. increased its position in Twist Bioscience by 67.5% in the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company's stock worth $9,301,000 after buying an additional 82,953 shares during the last quarter.

Twist Bioscience Trading Down 1.9 %

TWST stock traded down $0.73 on Wednesday, reaching $38.21. The company's stock had a trading volume of 1,546,412 shares, compared to its average volume of 944,777. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90. The firm has a market cap of $2.28 billion, a PE ratio of -11.30 and a beta of 2.15. The business has a fifty day simple moving average of $44.47 and a two-hundred day simple moving average of $45.23.

Remove Ads

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to analysts' expectations of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business's revenue was up 24.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.75) EPS. As a group, research analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, Director Robert Chess sold 5,000 shares of the firm's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00. Following the completion of the sale, the director now directly owns 16,641 shares in the company, valued at approximately $832,050. This trade represents a 23.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Emily M. Leproust sold 1,726 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $41.68, for a total transaction of $71,939.68. Following the completion of the transaction, the chief executive officer now owns 660,966 shares of the company's stock, valued at approximately $27,549,062.88. The trade was a 0.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,799 shares of company stock valued at $1,593,944 in the last three months. Company insiders own 3.01% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on TWST shares. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Wolfe Research began coverage on Twist Bioscience in a report on Friday, December 13th. They issued an "outperform" rating and a $60.00 price target on the stock. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday, February 4th. Barclays set a $58.00 target price on Twist Bioscience and gave the stock an "overweight" rating in a research note on Monday, February 3rd. Finally, JPMorgan Chase & Co. boosted their target price on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience currently has an average rating of "Moderate Buy" and a consensus target price of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.